Literature DB >> 10076916

Angiotensin II receptor pharmacology and AT1-receptor blockers.

O Chung1, T Csikós, T Unger.   

Abstract

Angiotensin II (Ang II) has diverse physiological actions leading, for example, to increases in extracellular volume, peripheral vascular resistance and blood pressure, and has also been implicated in the regulation of cell growth and differentiation. Molecular cloning and pharmacological studies have defined two major classes of Ang II receptors, designated as AT1 and AT2. Most effects of Ang II are mediated by AT1 receptors. Much less is known about the physiological role of AT2 receptors. Recent evidence suggests involvement of AT2 receptors in development, cell differentiation, apoptosis and regeneration in various tissues. AT1 and AT2 receptors have been shown to exert counteracting effects on cellular growth and differentiation, vascular tone and the release of arginine vasopressin (AVP). In each condition the AT2 receptor appears to down-modulate actions mediated by the AT1 receptor, resulting in decreased cellular proliferation, decreased levels of serum AVP levels or decreased vasoconstrictor responses. In addition, in neuronal cell lines, the AT2 receptor reportedly exerts antiproliferative effects and promotes neurite outgrowth, an effect accompanied by significant changes in the gene expression pattern of growth- and differentiation-related genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076916     DOI: 10.1038/sj.jhh.1000744

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

Review 1.  Irbesartan: an updated review of its use in cardiovascular disorders.

Authors:  A Markham; C M Spencer; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

2.  Modulation of body fluids and angiotensin II receptors in a rat model of intra-uterine growth restriction.

Authors:  Sophie Bédard; Benoit Sicotte; Jean St-Louis; Michèle Brochu
Journal:  J Physiol       Date:  2004-11-11       Impact factor: 5.182

Review 3.  The Pathophysiology of Long COVID throughout the Renin-Angiotensin System.

Authors:  Shaymaa Khazaal; Julien Harb; Mohamad Rima; Cédric Annweiler; Yingliang Wu; Zhijian Cao; Ziad Abi Khattar; Christian Legros; Hervé Kovacic; Ziad Fajloun; Jean-Marc Sabatier
Journal:  Molecules       Date:  2022-05-02       Impact factor: 4.927

4.  Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.

Authors:  Roberto Fogari; Amedeo Mugellini; Paola Preti; Annalisa Zoppi; Giuseppe Derosa
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

5.  Developmental effect of antenatal exposure to betamethasone on renal angiotensin II activity in the young adult sheep.

Authors:  Stephen A Contag; Jianli Bi; Mark C Chappell; James C Rose
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-13

Review 6.  Valsartan in the treatment of heart attack survivors.

Authors:  Bodh I Jugdutt
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Strengthening CoViD-19 therapy via combinations of RAS modulators.

Authors:  Veselina V Uzunova; Angel Todev; Jacqueline Zarkos; Daniel Addai; Julian Ananiev; Pavel Rashev; Radostina Alexandrova; Anna Tolekova
Journal:  Med Hypotheses       Date:  2021-03-25       Impact factor: 1.538

8.  Upregulation of ERK1/2-eNOS via AT2 receptors decreases the contractile response to angiotensin II in resistance mesenteric arteries from obese rats.

Authors:  Graziela N Hagihara; Nubia S Lobato; Fernando P Filgueira; Eliana H Akamine; Danielle S Aragão; Dulce E Casarini; Maria Helena C Carvalho; Zuleica B Fortes
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.